Mardepodect

Mardepodect

SCHEMBL439127

Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1.O=C(O)CCC(=O)O

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PDE10A

The experimentally established mechanism targets of Mardepodect. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PDE10A known ✓ Q9Y233 18/20 0.86
LGALS3 P17931 1/20 0.86
PDE4D Q08499 1/20 0.86
PDE4A P27815 7/20 0.67
PDE4B Q07343 7/20 0.67
PDE3B Q13370 6/20 0.67
PDE3A Q14432 6/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mardepodect SCHEMBL29430177 1.00 PDE10A (0.86) PDE10ALGALS3PDE4DPDE4APDE4B
SCHEMBL30123358 0.93 PDE10A (1.00) PDE10ALGALS3PDE4DPDE4APDE4B
SCHEMBL3271928 0.93 PDE10A (1.00) PDE10ALGALS3PDE4DPDE4APDE4B
Mardepodect SCHEMBL29496270 0.93 PDE10A (1.00) PDE10ALGALS3PDE4DPDE4APDE4B
Mardepodect SCHEMBL1414700 0.93 PDE10A (1.00) PDE10ALGALS3PDE4DPDE4APDE4B
Mardepodect SCHEMBL29435412 0.92 PDE10A (0.98) PDE10ALGALS3PDE4DPDE4APDE4B
Mardepodect SCHEMBL30357427 0.92 PDE10A (0.98) PDE10ALGALS3PDE4DPDE4APDE4B
SCHEMBL13772734 0.88 PDE10A (0.86) PDE10ALGALS3PDE4DPDE4APDE4B
SCHEMBL4870859 0.86 PDE10A (0.86) PDE10ALGALS3PDE4DPDE4APDE4B
Succinic Acid SCHEMBL441548 0.85 PDE10A (0.87) PDE10ALGALS3PDE4DPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117295731-A Prodrugs of PDE10 compounds 默沙东有限责任公司 2023-12-26 CN disclosed
EP-2763533-B1 TRIAZOLYL PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2021-12-29 EP disclosed
EP-2435048-B1 RADIOLABELED PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2019-07-03 EP disclosed
EP-2785183-B1 TRIAZOLOPYRIDINONE PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2018-12-19 EP disclosed
EP-2922823-B1 PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2018-10-31 EP disclosed
EP-2968324-B1 SUBSTITUTED PYRIDAZINONE DERIVATIVES AS PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2018-04-18 EP disclosed
EP-2919783-B1 CYCLOPROPYL IMIDAZOPYRIDINE PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2018-01-31 EP disclosed
EP-2621276-B1 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2017-12-27 EP disclosed
EP-2621926-B1 PYRAZOLOPYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2017-08-30 EP disclosed
EP-2919781-B1 CYCLOBUTYL BENZIMIDAZOLES AS PDE10 INHIBITORS MERCK SHARP & DOHME (US) 2017-06-28 EP disclosed
WO-2012058133-A1 ISOINDOLINONE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-05-03 WO disclosed
WO-2012054366-A2 SUBSTITUTED AMINO-TRIAZOLYL PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-04-26 WO disclosed
WO-2012044561-A2 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-04-05 WO disclosed
US-20120064005-A1 RADIOLABELED PDE10 INHIBITORS MERCK SHARP & DOHME LLC 2012-03-15 US disclosed
US-20120065211-A1 ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. 2012-03-15 US disclosed
US-20110319409-A1 7-AZA-QUINAZOLINE PDE10 INHIBITORS COX CHRISTOPHER D (US) 2011-12-29 US disclosed
WO-2011053559-A1 ARYL AMINOPYRIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-05-05 WO disclosed
WO-2010138585-A1 PYRIMIDINONES AS PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-12-02 WO disclosed
WO-2010138430-A1 ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-12-02 WO disclosed
WO-2010138577-A1 RADIOLABELED PDE10 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065211-A1 ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS PDE12, PDE4A, PDE5A PDE10A 6/4885LGALS3 4492/4885PDE4D 8/4885
US-20110319409-A1 7-AZA-QUINAZOLINE PDE10 INHIBITORS PDE5A, PDE12, PDE7B PDE10A 10/4885LGALS3 4738/4885PDE4D 13/4885
US-20120064005-A1 RADIOLABELED PDE10 INHIBITORS PDE5A, PDE3A, PDE10A PDE10A 3/4885LGALS3 4493/4885PDE4D 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.